- Home
- LAUR vs TMDX Comparison
LAUR vs TMDX Comparison
Compare LAUR & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAUR
- TMDX
- Stock Information
- Founded
- LAUR 1989
- TMDX 1998
- Country
- LAUR United States
- TMDX United States
- Employees
- LAUR 31800
- TMDX N/A
- Industry
- LAUR Other Consumer Services
- TMDX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- LAUR Real Estate
- TMDX Health Care
- Exchange
- LAUR Nasdaq
- TMDX Nasdaq
- Market Cap
- LAUR 4.3B
- TMDX 3.9B
- IPO Year
- LAUR 2017
- TMDX 2019
- Fundamental
- Price
- LAUR $29.41
- TMDX $118.44
- Analyst Decision
- LAUR Strong Buy
- TMDX Buy
- Analyst Count
- LAUR 2
- TMDX 11
- Target Price
- LAUR $29.50
- TMDX $125.40
- AVG Volume (30 Days)
- LAUR 1.3M
- TMDX 881.4K
- Earning Date
- LAUR 10-30-2025
- TMDX 10-27-2025
- Dividend Yield
- LAUR N/A
- TMDX N/A
- EPS Growth
- LAUR 35.40
- TMDX 2163.11
- EPS
- LAUR 1.68
- TMDX 2.02
- Revenue
- LAUR $1,552,343,000.00
- TMDX $531,292,000.00
- Revenue This Year
- LAUR $5.64
- TMDX $38.81
- Revenue Next Year
- LAUR $8.10
- TMDX $20.69
- P/E Ratio
- LAUR $17.35
- TMDX $58.50
- Revenue Growth
- LAUR 0.44
- TMDX 48.09
- 52 Week Low
- LAUR $15.15
- TMDX $55.00
- 52 Week High
- LAUR $31.74
- TMDX $145.50
- Technical
- Relative Strength Index (RSI)
- LAUR 50.75
- TMDX 48.73
- Support Level
- LAUR $28.91
- TMDX $112.79
- Resistance Level
- LAUR $30.00
- TMDX $120.28
- Average True Range (ATR)
- LAUR 0.72
- TMDX 4.69
- MACD
- LAUR -0.35
- TMDX -0.01
- Stochastic Oscillator
- LAUR 12.90
- TMDX 28.83
About LAUR Laureate Education Inc.
Laureate Education Inc is an international community of universities. The company provides higher education programs and services to students through an international network of licensed universities and higher education institutions. Its geographical segments include Peru and Mexico.
About TMDX TransMedics Group Inc.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.